Gastro-intestinal system
- GI1 Guideline for the use of laxatives to treat constipation
- Guidance to review Proton Pump Inhibitors
Cardiovascular system
- CV1 Guideline for the use of anticoagulants in atrial fibrillation
- AHSN guide to anticoagulants in atrial fibrillation
- CV2 Guideline for lipid management treatment (SLiMS)
- SLiMS supplement – PCSK9 inhibitors
Respiratory system
- RS1 Guideline for the treatment of asthma in adults
- RS2 Guideline for the choice of inhalers in asthma
- RS3 Guideline for the treatment of COPD
- RS4 Guideline for the choice of inhalers for COPD
- RS5 Guideline for the switching of inhalers in COPD
- RS6 Guideline for reducing ICS (inhaled corticosteroids) in COPD patients
Central nervous system
- CNS1 Guideline for the treatment of headache and migraine
- CNS2 SCCG Position Statement: nefopam
- CNS5 Guideline for reducing and stopping treatment with dosulepin
Pain
Infection
- INF1 NICE antimicrobial prescribing guidance *BASED ON LOCAL DATA CEFALEXIN IS FIRST LINE FOR URINARY TRACT INFECTION IN CHILDREN*
- INF2 Quick Reference Guide Antibiotic Prescribing in Adults and Children
- INF3 Risk assessment for Clostridium difficile infection
- INF4 Guideline for relapsing or recurrent UTI (taken from CHS)
- INF5 Sunderland Care Home Pragmatic UTI Guideline
Endocrine system
- Flash Glucose Monitoring System (FreeStyle Libre): North East and North Cumbria Joint Committee Position Statement, May 2019
- i-Port advance for use in children and adults with type 1 diabetes – Northern (NHS) Treatment Advisory Group decision summary
- END1 Guideline for the treatment of type2 diabetes in adults
- END2 Guidance on the self-monitoring of blood glucose in adults with type 2 diabetes
- Sunderland Diabetes Network: safe prescribing of insulin – for general practice
- Sunderland Diabetes Network: safe dispensing of insulin – for community pharmacy
- Information for patients: dapagliflozin, canagliflozin and empagliflozin (SGLT2 inhibitors) for type 2 diabetes
- END3 Guideline for use of gender dysphoria feminising hormones
- END4 Guideline for the use of gender dysphoria masculinising hormones
- END5 Guideline for the Treatment of Osteoporosis
- Sunderland-CCG-T2DM-guideline
Genito-urinary system
Blood and nutrition
- NUT1 Guideline for the initiationof Oral Nutritional Supplements ONS in Adults
- NUT2 Guideline for the prescribing of Oral Nutritional Supplements ONS in Adults
- NUT3 Quick Guide ONS
- NUT4 Guideline for the Prescribing of Infant Formula for Infants with suspected Cows Milk Protein Allergy or lactose intolerance
- NUT5 Guideline for gluten free prescribing v2.0
Eye
Skin
- SKIN1 Guideline for the prescribing of emollients
- Patient information leaflet: emollient information
- SKIN2 wound product formulary (adopted from CHS and South Tyneside Foundation Trust)
Appliances
- APP1 Guideline for the Prescribing of Stoma Products
- APP2 Guideline for the prescribing of rectal irrigation
Miscellaneous
- MISC3 Repeat Dispensing Guide to Mid-Batch Script Changes
- MISC4 Guidelines the Red/ Amber/ Green (RAG) System for Classifying Medicines in Sunderland Joint Formulary
- MISC5 NECS Useful Prescribing Information: A Guide For Prescribers
- MISC6 Patient Specific Directions
- MISC7 Procedure to add medicines, which may be prescribed elsewhere, to a patient’s record for information
- MISC10 NECS Individual Funding Request (IFR) Rapid Processing System
- MISC12 NHS England Guidance for GP Practice Cold Chain
- MISC13 Procedure for homely remedies in care homes
Position statements
- SCCG Position Statement Aliskiren
- SCCG Position Statement Alternative and complementary medicine
- SCCG Position Statement Amiodarone
- SCCG Position Statement Bath and shower preparations
- SCCG Position Statement Co-Proxamol
- SCCG Position statement Dosulepin
- SCCG Position statement Doxazosin MR
- SCCG Position Statement Dronedarone
- SCCG Position statement Glucosamine & Chondroitin
- SCCG Position Statement IR Fentanyl
- SCCG Position Statement Minocycline for Acne Vulgaris
- SCCG Position statement Needles for Insulin Pens
- SCCG Position statement Ocular supplements AMD
- SCCG Position statement Omega 3
- SCCG Position statement Perindopril arginine
- SCCG Position statement Rubefacients
- SCCG Position statement Silk garments
- SCCG Position statement Tadalafil once (Cialis® once-a-day)
- SCCG Position Statement Targinact
- SCCG Position statement Tramacet®
- SCCG Position statement Travel vaccines on NHS